GL-0719
Autoimmune diseases (e.g., Cold Agglutinin Disease)
Phase 2Active
Key Facts
About Gliknik
Founded in 2006, Gliknik is a private, pre-revenue biotech advancing a pipeline of proprietary recombinant Fc fusion proteins targeting autoimmune diseases and cancers. Its lead assets, GL-2045 and GL-0719, are both in clinical trials with patient dosing underway, aiming to address large markets with significant unmet needs. The company leverages expertise in immune system modulation and retains full ownership of its key programs, positioning it to capture significant value if successful. Leadership includes experienced industry veterans and scientific advisors with a track record in drug development.
View full company profile